

**NOAP CONFERENCE 2023
MRO TOXICOLOGY
PANEL**

DATE & TIME:
Wednesday May 17
1:30 – 4:00 PM

OUR PANEL

- Dr. Joe Jones: joe.jones@usdtl.com
- Dr. Donna Smith: DrDonna@recoverytrek.com
- Dr. Anthony Costantino tonytox@gmail.com
- Dr. James Ferguson: JFerguson@vaulthealth.com
- Dr. Barry Lubin: blubin@affinitysolutions.com

EDUCATIONAL OBJECTIVES

1. Participant will be able to describe the different laboratory certifications, the minimum certifications that should be in place for regulatory testing, what steps should be taken to evaluate a collection site's competency and to what degree are DOT (Department of Transportation drug testing rules applicable to regulatory healthcare practitioner monitoring).
2. Participant will be able to describe the different laboratory certifications, the minimum certifications that should be in place for regulatory testing, what steps should be taken to evaluate a collection site's competency and to what degree are DOT (Department of Transportation drug testing rules applicable to regulatory healthcare practitioner monitoring).
3. Participant will be able to describe collection procedures for a directly observed collection, policies and procedures in response to shy bladder, inability to void at collection site, totally shaved when reports for hair analysis, repeated dilute specimen results and allegation of collection site errors. Included will be specific medical evaluations required in response to these events.

4. Participant will be able to describe the role of the MRO, suggested procedure for participant contested results and the steps the MRO takes in the donor interview and the final report.
5. Participant will be able to describe the new drugs that the MROs are encountering including but not limited to kratom, xylazine (animal sedative), tianeptine (also known as gas station heroin, and Tianna) and others including if can they be tested for.
6. Participant will be able to describe common medications that may cause a false positive result.

Dr Donna Smith

Would you please Describe the different laboratory certifications and the minimum certifications that should be in place for regulatory testing of healthcare professionals.

What steps should be taken to evaluate a collection site's competency and to what degree are DOT (Department of Transportation) drug testing rules applicable to regulatory healthcare practitioner monitoring.

Dr. James Ferguson

Would you please Describe the role of the MRO.

Describe the suggested procedure if a participant contests the results of a drug screen.

Describe the steps the MRO takes including the components of the MRO interview with the participant and the content of the final report to the monitoring agency.

If time permits, please describe what is included in a litigation packet.

Dr. Barry Lubin

Would you please Describe the collection procedures for a directly observed collection.

Describe suggested policies and procedures in response to a participant claiming a) inability to void at collection site b) a "shy Bladder" c) to be hairless as they are totally shaved when appear for a hair analysis d) participant alleges collection site errors e) if participant has repeated dilute specimen results.

Please outline for us suggested specific medical evaluations that should be required in response to these events.

Dr. Anthony Costantino

Would you please Describe what "assay interference" means.

Describe the spirometry and chromatography processes along with other confirmation methods.

Describe what the second laboratory does when testing a split specimen to reconfirm a positive.

Dr. Joe Jones

Would you please Describe the various modalities for drug testing including but not limited to urine, blood, hair and nails.

Describe any special considerations that the Case Manager should be aware of including effects of hair products - dyes, shampoos, conditioners, styling products and hair weaves, effects of nail polish - gel, powder and traditional nail polish and any others that you may be asked.

Would you also describe detection windows for the different types of collections and common medications that can cause a false positive.

Dr. Barry Lubin

GAS STATION DRUGS:

Would you please Describe the new drugs that our participants may be using and those that MROs are encountering including but not limited to kratom, xylazine (animal sedative), tianeptine (also known as gas station heroin (ZAZA , Coaxil, Tianna, TD Red, Pegasus), THC in Vapes, and others.

Is there a drug screen that can detect them?

Should we be testing for kratom, xylazine, tianeptine or others? Is this testing cost prohibitive>

ALL PANEL MEMBERS

QUESTIONS FROM THE AUDIENCE

???????

THANK YOU! THANK YOU! THANK YOU!

These illustrious Doctors have been supportive of NOAP for over 15 Years and give freely of their time and expertise to all of us.

Please let's hear a rousing thank you for a fabulous presentation!!